TNFAIP3 and acute lymphoblastic leukemia: There was a clear trend toward poor OS for T‐ALL patients with a TNFAIP3 mutation although the data were not statistically significant (hazard ratio (HR) = 1.90; 95% confidence interval (CI): 0.89–4.07; 3‐year OS: 20% vs. 43%; p = 0.092).